CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION

BACKGROUND: The cyclin D-CDK4/6-Rb pathway is activated in most glioblastomas. Abemaciclib is a potent CDK4/6 inhibitor with good brain penetration approved for ER/PR/HER2- breast cancer. In order to efficiently evaluate the potential impact of abemaciclib on overall survival (OS) in newly diagnosed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Wen, Patrick, Trippa, Lorenzo, Lee, Eudocia, Fell, Geoffrey, Rahman, Rifaquat, Arrillaga-Romany, Isabel, Touat, Mehdi, McCluskey, Christine, Brunno, Jennifer, Gaffey, Sarah, Drappatz, Jan, Lassman, Andrew, Galanis, Evanthia, Ahluwalia, Manmeet, Colman, Howard, Nabors, Louis, Hepel, Jaroslaw, Elinzano, Heinrich, Schiff, David, Chukwueke, Ugonma, Beroukhim, Rameen, Nayak, Lakshmi, Mcfaline-Figueroa, Jose, Batchelor, Tracy, Rinne, Mikael, Kaley, Thomas, Lu-Emerson, Christine, Bi, Wenya Linda, Arnaout, Omar, Peruzzi, Pier-Paolo, Doherty, Lisa, Haas-Kogan, Daphne, Tanguturi, Shyam, Cagney, Daniel, Aizer, Ayal A, Welch, Mary, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Geduldig, Jack, Santagata, Sandro, Meredith, David, Chiocca, E Antonio, Reardon, David, Ligon, Keith, Alexander, Brian
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650442/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.179
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi